Look for Drugs and Conditions

Representative Image

Leqembi Can Be Safely Given in Memory Clinics, Study Finds

In a significant reassurance for patients and clinicians alike, a new real-world study published in JAMA Neurology has found that Leqembi (lecanemab), the first FDA-approved drug shown to slow the progression of Alzheimer’s disease, can be safely administered in memory clinics—despite earlier concerns about serious side effects.


Approved in 2023, Leqembi works by helping the body clear amyloid beta proteins, which contribute to the formation of toxic plaques in the brains of Alzheimer’s patients. While clinical trials showed the drug offered modest benefits in slowing cognitive decline, they also raised alarms about risks of brain swelling and bleeding—known medically as ARIA (amyloid-related imaging abnormalities).

The latest findings, however, offer encouraging news. “Fear surrounding the drug’s potential side effects can lead to treatment delays,” said Dr. Barbara Joy Snider, co-senior researcher and professor of neurology at Washington University School of Medicine in St. Louis. “Our findings show that memory clinics have the infrastructure and expertise to safely administer and care for patients on lecanemab, including the few who may experience severe side effects.”

The study monitored 234 patients with very mild or mild Alzheimer’s disease who received Leqembi infusions at Washington University’s Memory Diagnostic Center between August 2023 and October 2024. Among the 194 patients identified as being at higher risk for brain-related side effects, approximately 22% developed ARIA.

Importantly, most cases of brain swelling or bleeding were asymptomatic and only detected through routine brain imaging. Of the 11 patients who experienced symptoms, all recovered within a few months, and no fatalities were reported.

The study’s findings suggest that with appropriate monitoring and specialized care, Leqembi can be safely integrated into real-world clinical settings. This could mark a turning point for many families battling the early stages of Alzheimer’s disease, offering new hope without compromising safety.

The research is expected to boost confidence among healthcare providers and patients, potentially leading to broader adoption of the drug in clinical practice.


0 Comments
Be first to post your comments

Post your comment

Related Articles

Ad 5